Ontology highlight
ABSTRACT:
SUBMITTER: Li J
PROVIDER: S-EPMC5809840 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
Journal of hematology & oncology 20180213 1
Recently, the US Food and Drug Administration (FDA) approved the first chimeric antigen receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic leukemia. While CAR-T has achieved remarkable success in the treatment of hematopoietic malignancies, whether it can benefit solid tumor patients to the same extent is still uncertain. Even though hundreds of clinical trials are undergoing exploring a variety of tumor-associated antigens (TAA), no such antigen with comp ...[more]